CYTK:NASDAQCytokinetics, Incorporated Analysis
Data as of 2026-06-18 - not real-time
$78.11
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Cytokinetics is trading in a bullish technical environment, with the short‑term moving average positioned above longer‑term averages and a bullish MACD histogram supporting upward momentum.
The stock benefits from recent positive analyst coverage, including a new buy rating from Citi, and a strategic launch of MYQORZO in Germany, which together reinforce short‑term upside potential despite a fundamentally weak balance sheet characterized by negative margins, cash burn and a sizable debt load.
The stock benefits from recent positive analyst coverage, including a new buy rating from Citi, and a strategic launch of MYQORZO in Germany, which together reinforce short‑term upside potential despite a fundamentally weak balance sheet characterized by negative margins, cash burn and a sizable debt load.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and RSI indicating strong momentum
- Upcoming MYQORZO launch in Germany providing near‑term catalyst
- Increasing volume supporting price strength
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Citi’s new buy coverage adding analyst confidence
- Pipeline progression across multiple cardiac indications
- Market sentiment reflected by an extreme greed index
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Continued cash burn and high debt relative to cash assets
- Uncertainty around regulatory approvals for late‑stage candidates
- Current valuation appears stretched given negative earnings
Key Metrics & Analysis
Financial Health
Revenue Growth1125.80%
P/E Ratio-16.4
ROA-31.54%
P/B Ratio-11.7
Op. Cash Flow$-523848992
Free Cash Flow$-381057760
Industry P/E24.3
Technical Analysis
TrendBullish
RSI62.8
Support$66.63
Resistance$79.30
MA 20$73.37
MA 50$70.67
MA 200$63.57
MACDBullish
VolumeIncreasing
Fear & Greed Index88.5
Valuation
Target Price$104.70
Upside/Downside34.04%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.79
Volatility41.75%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.